Design and rationale of dabigatran's stroke prevention in real life in Turkey (D-SPIRIT)

Design and rationale of dabigatran's stroke prevention in real life in Turkey (D-SPIRIT)

Objective: The D-SPIRIT registry is designed to investigate the safety and efficacy of dabigatran etexilate in patients with nonvalvular atrial fibrillation (NVAF) and to collect data on outcomes in clinical practice. Methods: The D-SPIRIT is a national, prospective, observational, post-marketing...

Full description

Bibliographic Details
Main Authors:	Uğur Önsel Türk, Emin Alioğlu, Eşref Tunçer, Mehmet Emre Özpelit, Nihat Pekel, İstemihan Tengiz, Nurullah Çetin, Onur Dalgıç, Caner Topaloğlu, Nazile Bilgin, Cihan Altın, Tolga Özdemirkıran, Kamil Tülüce, Ebru İpek Türkoğlu, Ebru Özpelit
Format:	Article
Language:	English
Published:	KARE Publishing 2016-05-01
Series:	Türk Kardiyoloji Derneği Arşivi
Subjects:	atrial fibrillation dabigatran etexilate; prevention; registry stroke; turkey
Online Access:	https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tkd&un=TKDA-37209

Similar Items

Dabigatran for stroke prevention in real life in a sample of population from Turkey: D-SPIRIT registry
by: Cihan Altın, et al.
Published: (2021-12-01)

Design and synthesis of dabigatran etexilate derivatives with inhibiting thrombin activity for hepatocellular carcinoma treatment
by: Zhuo-song Xie, et al.
Published: (2024-01-01)

Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations
by: E. I. Baranova, et al.
Published: (2019-11-01)

Dabigatran in the prevention of stroke in nonvalvular atrial fibrillation: Complex clinical situations and real clinical practice
by: O N Tkacheva, et al.
Published: (2014-04-01)

New indications for dabigatran: A suggestion from a drug use evaluation study
by: Farzaneh Ashrafi, et al.
Published: (2017-01-01)

Pharmacokinetics and Pharmacogenetics of Dabigatran
by: A. V. Savinova, et al.
Published: (2021-03-01)

Dabigatran in the prevention of venous thromboembolism after major orthopedic surgery
by: Orietta Zaniolo
Published: (2009-09-01)

Bioequivalence and pharmacodynamics of a generic dabigatran etexilate capsule in healthy Chinese subjects under fasting and fed conditions
by: Xin Li, et al.
Published: (2020-04-01)

PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION
by: E. D. Kosmacheva, et al.
Published: (2015-09-01)

Monitoring the use of dabigatran etexilate for stroke prevention: compliance with renal function guidelines
by: Alesha J. Smith, et al.
Published: (2020-01-01)

Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials
by: Rosencher Nadia, et al.
Published: (2012-06-01)

Spinal subarachnoid and subdural hematoma presenting as a Brown-Séquard-like myelopathy following minor trauma in a patient on dabigatran etexilate
by: Allen R. Wolfe, MD, MPH, et al.
Published: (2017-06-01)

Investigation of Solid-State Hydrate-Anhydrous Phase Transformations of Dabigatran Etexilate Hemi-Edisylate
by: Jin Feng, et al.
Published: (2023-03-01)

Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation
by: Bryan H. Simpson, et al.
Published: (2019-07-01)

Choice of Renal Function Estimator Influences Adverse Outcomes with Dabigatran Etexilate in Patients with Atrial Fibrillation
by: Bryan H. Simpson, et al.
Published: (2018-10-01)

Thromboprophylaxis with dabigatran after total hip arthroplasty in Indian patients: A subanalysis of a double-blind, double-dummy, randomized RE-NOVATE II study
by: Rajesh Malhotra, et al.
Published: (2017-03-01)

Dabigatran etexilate: a direct thrombin inhibitor
by: M. Dugnani
Published: (2013-05-01)

Recovery of Visual Function after Administration of Dabigatran Etexilate
by: Carl-Ludwig Schönfeld, et al.
Published: (2014-08-01)

The Complementary Effects of Dabigatran Etexilate and Exercise Training on the Development and Stability of the Atherosclerotic Lesions in Diabetic ApoE Knockout Mice
by: Nikolaos PE Kadoglou, et al.
Published: (2023-10-01)

Dabigatran etexilate, a novel oral direct thrombin inhibitor, for preventing thromboembolic events after knee replacement arthroplasty
by: Moghtadaee M, et al.
Published: (2012-02-01)

The fifth anniversary of clinical use of new oral anticoagulants in non-valvular atrial fibrillation
by: A. V. Fonyakin
Published: (2015-06-01)

Ex-vivo Ex-Vivo Absorption Study of a Novel Dabigatran Etexilate Loaded Nanostructured Lipid Carrier Using Non-Everted Intestinal Sac Model
by: haithem N Abed, et al.
Published: (2019-12-01)

Dabigatran Etexilate Induces Cytotoxicity in Rat Gastric Epithelial Cell Line via Mitochondrial Reactive Oxygen Species Production
by: Hiromi Kurokawa, et al.
Published: (2021-09-01)

Budget impact analysis resulting from the use of dabigatran etexilate in preventing stroke in patients with non-valvular atrial fibrillation in Italy
by: Francesco Mennini, et al.
Published: (2012-09-01)

The novel anticoagulants: entering a new era
by: Swiss Medical Weekly
Published: (2009-02-01)

Periprocedural Direct Oral Anticoagulant Management: The RA-ACOD Prospective, Multicenter Real-World Registry
by: Raquel Ferrandis, et al.
Published: (2020-04-01)

Dabigatran etexilate in the prevention of cardioembolic complications in patients with non-valvular atrial fibrillation
by: IS Yavelov
Published: (2014-12-01)

Stable coronary artery disease management: What has changed in the 2013 European Society of Cardiology guideline?
by: M. Emre Özpelit, et al.
Published: (2014-02-01)

New safety standards for anticoagulant therapy in the treatment of atrial fibrillation
by: E. I. Baranova
Published: (2018-11-01)

Direct oral anticoagulants: a guide for daily practice
by: Pierre Fontana, et al.
Published: (2016-02-01)

Ethyl 3-[3-amino-4-methylamino-N-(pyridin-2-yl)benzamido]propanoate
by: Gao-Ju Wen, et al.
Published: (2017-02-01)

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
by: Jong-Min Kim, et al.
Published: (2022-01-01)

Clinical performance of the atrial fibrillation in the Russian population depending on the antithrombotic therapy: findings from the GLORIA-AF registry phase 2
by: E. V. Shlyakhto, et al.
Published: (2020-12-01)

Systemic Thrombolytic Therapy for Ischemic Stroke in the Course of Anticoagulants
by: L. Kh.-B. Akhmatkhanova, et al.
Published: (2021-11-01)

Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants
by: Perka Carsten
Published: (2011-11-01)

The new way of Dabigatran reversal – Idarucizumab
by: Erwin Ciechański, et al.
Published: (2019-02-01)

The new way of Dabigatran reversal – Idarucizumab
by: Erwin Ciechański, et al.
Published: (2019-02-01)

Dabigatran for left ventricular thrombus
by: Satishkumar Kolekar, et al.
Published: (2015-09-01)

Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran
by: Giannandrea D, et al.
Published: (2019-05-01)

Idarucizumab for Dabigatran Reversal-full Cohort Analysis (RE-VERSE AD Study)
by: Esme Ekizoğlu
Published: (2018-06-01)